NES
PCRX icon

New England Securities’s Pacira BioSciences PCRX Stock Holding History

New England Securities’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-60
Closed -$4K – 1802
2014
Q1 		$4K Buy
+60
New +$4.08K ﹤0.01% 1344

Other funds holding PCRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

New England Securities's PCRX Position: Q2 2014 in Review

New England Securities sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 60 shares — an estimated $4K sold.

New England Securities first reported a position in PCRX in Q1 2014 and held it in 1 quarter. The position peaked at $4K in Q1 2014. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

  • New England Securities reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
  • New England Securities sold 60 Pacira BioSciences shares in Q2 2014, an estimated $4K.
  • New England Securities first reported a position in Pacira BioSciences in Q1 2014 and held it in 1 quarter.
  • New England Securities's Pacira BioSciences position peaked at $4K in Q1 2014.
  • 191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on New England Securities's 13F filing for Q2 2014, filed 4 Aug 2014.